LBTS.F logo

Almirall OTCPK:LBTS.F Stock Report

Last Price

US$9.51

Market Cap

US$1.8b

7D

0%

1Y

n/a

Updated

27 Mar, 2024

Data

Company Financials +

LBTS.F Stock Overview

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

LBTS.F fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance0/6
Financial Health6/6
Dividends2/6

Almirall, S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Almirall
Historical stock prices
Current Share Price€9.51
52 Week High€10.18
52 Week Low€8.85
Beta0.32
1 Month Change0%
3 Month Change4.51%
1 Year Changen/a
3 Year Change-32.07%
5 Year Change-44.16%
Change since IPO8.88%

Recent News & Updates

Recent updates

Shareholder Returns

LBTS.FUS PharmaceuticalsUS Market
7D0%-0.2%0.6%
1Yn/a23.9%29.5%

Return vs Industry: Insufficient data to determine how LBTS.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how LBTS.F performed against the US Market.

Price Volatility

Is LBTS.F's price volatile compared to industry and market?
LBTS.F volatility
LBTS.F Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement9.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: LBTS.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine LBTS.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19431,904Carlos Gallardo Piquéhttps://www.almirall.com

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer.

Almirall, S.A. Fundamentals Summary

How do Almirall's earnings and revenue compare to its market cap?
LBTS.F fundamental statistics
Market capUS$1.85b
Earnings (TTM)-US$41.65m
Revenue (TTM)US$973.03m

1.9x

P/S Ratio

-44.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LBTS.F income statement (TTM)
Revenue€898.79m
Cost of Revenue€235.30m
Gross Profit€663.49m
Other Expenses€701.96m
Earnings-€38.47m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 13, 2024

Earnings per share (EPS)-0.18
Gross Margin73.82%
Net Profit Margin-4.28%
Debt/Equity Ratio24.4%

How did LBTS.F perform over the long term?

See historical performance and comparison

Dividends

2.3%

Current Dividend Yield

-97%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.